Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acceptable Safety
20%
Adverse Events
20%
Alkylating Agents
20%
Aminotransferase Levels
20%
Antitumor Activity
40%
B Lymphocytes
20%
B-cell Receptor Signaling
20%
Complete Response
20%
Diarrhea
20%
Duration of Response
40%
Follicular Lymphoma
20%
Group Studies
20%
Idelalisib
100%
Indolent Lymphoma
100%
Indolent non-Hodgkin Lymphoma
100%
Lymphoplasmacytic Lymphoma
20%
Marginal Zone Lymphoma
20%
Median Progression-free Survival
20%
Median Time
20%
Microenvironment
20%
Neutropenia
20%
Orally Active
20%
Overall Rate
20%
Phase 1 Study
20%
Phase II Study
20%
Phosphatidylinositol 3-kinase delta
100%
Pneumonia
20%
Previously Treated
20%
Prior Treatment
20%
Progression-free Survival
20%
Response Rate
60%
Rituximab
20%
Safety Profile
20%
Single Group
40%
Small Lymphocytic Lymphoma
20%
Twice Daily
20%
Waldenström Macroglobulinemia
20%
Medicine and Dentistry
Adverse Event
20%
Alkylating Antineoplastic Agent
20%
Antineoplastic Activity
40%
B Lymphocyte
20%
B Lymphocyte Receptor
20%
Diarrhea
20%
Diseases
20%
Follicular Lymphoma
20%
Idelalisib
100%
Lymphocytic Lymphoma
20%
MALT Lymphoma
20%
Neutropenia
20%
Non-Hodgkin Lymphoma
100%
Phosphoinositide 3-Kinase
100%
Progression Free Survival
40%
Rituximab
20%
Transaminase
20%
Waldenström's Macroglobulinemia
40%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
20%
Alkylating Agent
20%
Aminotransferase
20%
Antitumor Activity
40%
B Lymphocyte Receptor
20%
Diarrhea
20%
Diseases
20%
Follicular Lymphoma
20%
Idelalisib
100%
Lymphocytic Lymphoma
20%
Marginal Zone Lymphoma
20%
Neutropenia
20%
Nonhodgkin Lymphoma
100%
Phosphatidylinositol 3 Kinase
100%
Progression Free Survival
40%
Rituximab
20%
Waldenstroem macroglobulinemia
40%